FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386996617> ?p ?o ?g. }

• W4386996617 endingPage "9" @default.
• W4386996617 startingPage "1" @default.
• W4386996617 abstract "ABSTRACTIntroduction Metastatic triple-negative breast cancer (TNBC) is an aggressive sub-type of breast cancer. Despite recent advances, metastatic TNBC remains difficult to treat with limited targeted treatment options. Fam-trastuzumab deruxtecan (T-DXd), is a novel antibody-drug conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2) and is composed of a unique linker bound to the topoisomerase I inhibitor DXd. T-DXd has significant anti-tumor activity in patients with HER2-low TNBC.Areas Covered This review reports on the mechanism, pre-clinical/clinical studies, efficacy, and tolerability of T-DXd. A literature search was conducted via PubMed using keywords such as ‘fam-trastuzumab deruxtecan,’ ‘Enhertu,’ and ‘HER2-low cancers.’Expert Opinion The Phase III Destiny-Breast04 Trial showed benefit in progression-free and overall survival in patients with HER2-low metastatic breast cancers treated with T-DXd compared to treatment of physician’s choice chemotherapy. T-DXd is the first pharmaceutical to effectively target a HER2-low population with clinically meaningful efficacy in patients with HER2-low TNBC. Compared to chemotherapy, T-DXd has a similar safety profile, with the additional need for close monitoring for interstitial lung disease. Given the clinical activity of T-DXd in TNBC, it is likely there will be continued efforts to refine HER2-low diagnostics and to develop additional ADCs with other protein targets.KEYWORDS: Antibody-drug conjugate (ADC)fam-trastuzumab deruxtecan (T-DXd)human epidermal growth factor receptor 2 (HER2)-lowtriple-negative breast cancer (TNBC)topoisomerase I Article highlights Triple-negative breast cancer (TNBC) lacks the expression of the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) amplification.Immunotherapy, poly (ADP-ribose) polymerase (PARP) inhibitors, and the antibody-drug conjugate (ADC) sacituzumab govitecan represent recent advances in the treatment of metastatic TNBC. Despite these advances, survival remains inferior compared to other breast cancer subtypes and there is a continued need for novel effective therapies.Fam-trastuzumab deruxtecan (T-DXd) is an ADC, targeting HER2, composed of a novel peptide linker and a payload derived from the topoisomerase I inhibitor, DX-8951 (DXd).In preclinical studies, T-DXd was found to have anti-tumor activity in HER2-low cancer cells, in addition to HER2-positive models.In a Phase I, two-part study, T-DXd showed anti-tumor activity in a heavily pre-treated HER2-low metastatic or advanced breast cancer population.In the Phase III Destiny-Breast04 trial, patients with advanced or metastatic HER2-low breast cancer, had superior progression-free survival (PFS) and overall survival (OS) when treated with T-DXd compared to treatment of physician’s choice (TPC) chemotherapy. This benefit was observed in both the hormone receptor (HR)-positive and TNBC populations.In the Destiny-Breast04 trial, side effects were similar in patients treated with T-DXd or TPC. Notably, more cases of pneumonitis or interstitial lung disease occurred in the T-DXd group. Physicians should be diligent in monitoring patients treated with T-DXd for pneumonitis and promptly initiate glucocorticosteroid treatment and stop T-DXd if this toxicity is observed.The success of T-DXd in HER2-low breast cancer will likely spur the development of newer therapeutics and impact how HER2-low breast cancers are treated.Declaration of interestThe authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.Reviewer disclosuresA reviewer on this paper has received research funding from Pfizer, Roche, has served on the advisory boards of Seagen, AstraZeneca, Pfizer, Roche, has received speakers fees from Seagen, AstraZeneca, Pfizer, Roche, Gilead, Lilly, Esai and has received conference support from AstraZeneca, Lilly, Roche.Additional informationFundingThis paper received no funding." @default.
• W4386996617 created "2023-09-25" @default.
• W4386996617 creator A5020076611 @default.
• W4386996617 creator A5020149153 @default.
• W4386996617 creator A5044804678 @default.
• W4386996617 creator A5090647064 @default.
• W4386996617 date "2023-09-24" @default.
• W4386996617 modified "2023-10-14" @default.
• W4386996617 title "The emergence of targeted therapy for HER2-low triple-negative breast cancer: a review of fam-trastuzumab deruxtecan" @default.
• W4386996617 cites W1988373577 @default.
• W4386996617 cites W2058114203 @default.
• W4386996617 cites W2064394610 @default.
• W4386996617 cites W2115100262 @default.
• W4386996617 cites W2314772071 @default.
• W4386996617 cites W2387397851 @default.
• W4386996617 cites W2413318407 @default.
• W4386996617 cites W2417431203 @default.
• W4386996617 cites W2621271973 @default.
• W4386996617 cites W2760931533 @default.
• W4386996617 cites W2806074020 @default.
• W4386996617 cites W2808864948 @default.
• W4386996617 cites W2809293192 @default.
• W4386996617 cites W2886477543 @default.
• W4386996617 cites W2897422388 @default.
• W4386996617 cites W2898328653 @default.
• W4386996617 cites W2913584903 @default.
• W4386996617 cites W2942867242 @default.
• W4386996617 cites W2953684910 @default.
• W4386996617 cites W2968565789 @default.
• W4386996617 cites W2990398119 @default.
• W4386996617 cites W2994917610 @default.
• W4386996617 cites W2999400187 @default.
• W4386996617 cites W3005585857 @default.
• W4386996617 cites W3016619323 @default.
• W4386996617 cites W3018222852 @default.
• W4386996617 cites W3042830787 @default.
• W4386996617 cites W3119128530 @default.
• W4386996617 cites W3156985612 @default.
• W4386996617 cites W3166815374 @default.
• W4386996617 cites W3169973594 @default.
• W4386996617 cites W3197851884 @default.
• W4386996617 cites W3206286748 @default.
• W4386996617 cites W4220884574 @default.
• W4386996617 cites W4220923708 @default.
• W4386996617 cites W4221100806 @default.
• W4386996617 cites W4226068292 @default.
• W4386996617 cites W4281619692 @default.
• W4386996617 cites W4281640394 @default.
• W4386996617 cites W4281998421 @default.
• W4386996617 cites W4285992810 @default.
• W4386996617 cites W4286001412 @default.
• W4386996617 cites W4295905572 @default.
• W4386996617 cites W4296004823 @default.
• W4386996617 cites W4306155108 @default.
• W4386996617 cites W4306702005 @default.
• W4386996617 cites W4306739715 @default.
• W4386996617 cites W4308766741 @default.
• W4386996617 cites W4319749520 @default.
• W4386996617 cites W4380264010 @default.
• W4386996617 doi "https://doi.org/10.1080/14737140.2023.2257885" @default.
• W4386996617 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37742278" @default.
• W4386996617 hasPublicationYear "2023" @default.
• W4386996617 type Work @default.
• W4386996617 citedByCount "0" @default.
• W4386996617 crossrefType "journal-article" @default.
• W4386996617 hasAuthorship W4386996617A5020076611 @default.
• W4386996617 hasAuthorship W4386996617A5020149153 @default.
• W4386996617 hasAuthorship W4386996617A5044804678 @default.
• W4386996617 hasAuthorship W4386996617A5090647064 @default.
• W4386996617 hasConcept C121608353 @default.
• W4386996617 hasConcept C126322002 @default.
• W4386996617 hasConcept C143998085 @default.
• W4386996617 hasConcept C159654299 @default.
• W4386996617 hasConcept C197934379 @default.
• W4386996617 hasConcept C203014093 @default.
• W4386996617 hasConcept C2775930923 @default.
• W4386996617 hasConcept C2777325958 @default.
• W4386996617 hasConcept C2778375690 @default.
• W4386996617 hasConcept C2779786085 @default.
• W4386996617 hasConcept C2780110267 @default.
• W4386996617 hasConcept C530470458 @default.
• W4386996617 hasConcept C535046627 @default.
• W4386996617 hasConcept C542903549 @default.
• W4386996617 hasConcept C71924100 @default.
• W4386996617 hasConceptScore W4386996617C121608353 @default.
• W4386996617 hasConceptScore W4386996617C126322002 @default.
• W4386996617 hasConceptScore W4386996617C143998085 @default.
• W4386996617 hasConceptScore W4386996617C159654299 @default.
• W4386996617 hasConceptScore W4386996617C197934379 @default.
• W4386996617 hasConceptScore W4386996617C203014093 @default.
• W4386996617 hasConceptScore W4386996617C2775930923 @default.
• W4386996617 hasConceptScore W4386996617C2777325958 @default.
• W4386996617 hasConceptScore W4386996617C2778375690 @default.
• W4386996617 hasConceptScore W4386996617C2779786085 @default.
• W4386996617 hasConceptScore W4386996617C2780110267 @default.
• W4386996617 hasConceptScore W4386996617C530470458 @default.
• W4386996617 hasConceptScore W4386996617C535046627 @default.
• W4386996617 hasConceptScore W4386996617C542903549 @default.

• next